| Exosome-mediated delivery of hydrophobically modified siRNA for huntingtin mRNA silencing MC Didiot, LM Hall, AH Coles, RA Haraszti, BMDC Godinho, K Chase, ... Molecular Therapy 24 (10), 1836-1847, 2016 | 566 | 2016 |
| A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system JF Alterman, BMDC Godinho, MR Hassler, CM Ferguson, D Echeverria, ... Nature biotechnology 37 (8), 884-894, 2019 | 250 | 2019 |
| Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo A Biscans, A Coles, R Haraszti, D Echeverria, M Hassler, M Osborn, ... Nucleic acids research 47 (3), 1082-1096, 2019 | 226 | 2019 |
| Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo MR Hassler, AA Turanov, JF Alterman, RA Haraszti, AH Coles, MF Osborn, ... Nucleic acids research 46 (5), 2185-2196, 2018 | 208 | 2018 |
| Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain JF Alterman, LM Hall, AH Coles, MR Hassler, MC Didiot, K Chase, ... Molecular therapy Nucleic acids 4, 2015 | 207 | 2015 |
| RNAi modulation of placental sFLT1 for the treatment of preeclampsia AA Turanov, A Lo, MR Hassler, A Makris, A Ashar-Patel, JF Alterman, ... Nature biotechnology 36 (12), 1164-1173, 2018 | 206 | 2018 |
| Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways MF Osborn, AH Coles, A Biscans, RA Haraszti, L Roux, S Davis, S Ly, ... Nucleic acids research 47 (3), 1070-1081, 2019 | 156 | 2019 |
| Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ... Nature Communications 9 (1), 2641, 2018 | 141 | 2018 |
| Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain M Nikan, MF Osborn, AH Coles, BMDC Godinho, LM Hall, RA Haraszti, ... Molecular therapy Nucleic acids 5, 2016 | 119 | 2016 |
| Optimized cholesterol-siRNA chemistry improves productive loading onto extracellular vesicles RA Haraszti, R Miller, MC Didiot, A Biscans, JF Alterman, MR Hassler, ... Molecular Therapy 26 (8), 1973-1982, 2018 | 113 | 2018 |
| Serum deprivation of mesenchymal stem cells improves exosome activity and alters lipid and protein composition RA Haraszti, R Miller, ML Dubuke, HE Rockwell, AH Coles, E Sapp, ... Iscience 16, 230-241, 2019 | 109 | 2019 |
| Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer PO Gannon, J Godin-Ethier, M Hassler, N Delvoye, M Aversa, AO Poisson, ... PloS one 5 (8), e12107, 2010 | 83 | 2010 |
| Fully stabilized asymmetric sirna A Khvorova, N Aronin, M Hassler, J Alterman US Patent App. 15/089,423, 2016 | 81 | 2016 |
| Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid … BMDC Godinho, JW Gilbert, RA Haraszti, AH Coles, A Biscans, L Roux, ... nucleic acid therapeutics 27 (6), 323-334, 2017 | 66 | 2017 |
| Bis-diimidazolylidine complexes of nickel: Investigations into nickel catalyzed coupling reactions TAP Paulose, SC Wu, JA Olson, T Chau, N Theaker, M Hassler, JW Quail, ... Dalton Transactions 41 (1), 251-260, 2012 | 62 | 2012 |
| Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs MF Osborn, JF Alterman, M Nikan, H Cao, MC Didiot, MR Hassler, ... Nucleic acids research 43 (18), 8664-8672, 2015 | 52 | 2015 |
| Novel cluster and monomer-based GalNAc structures induce effective uptake of siRNAs in vitro and in vivo VK Sharma, MF Osborn, MR Hassler, D Echeverria, S Ly, EA Ulashchik, ... Bioconjugate chemistry 29 (7), 2478-2488, 2018 | 48 | 2018 |
| Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models F Conroy, R Miller, JF Alterman, MR Hassler, D Echeverria, ... Nature communications 13 (1), 5802, 2022 | 47 | 2022 |
| Cell type impacts accessibility of mRNA to silencing by RNA interference CM Ferguson, D Echeverria, M Hassler, S Ly, A Khvorova Molecular Therapy Nucleic Acids 21, 384-393, 2020 | 46 | 2020 |
| An RNAi therapeutic targeting hepatic DGAT2 in a genetically obese mouse model of nonalcoholic steatohepatitis B Yenilmez, N Wetoska, M Kelly, D Echeverria, K Min, L Lifshitz, ... Molecular Therapy 30 (3), 1329-1342, 2022 | 43 | 2022 |
Anastasia KhvorovaUMASS Medical SchoolVerified email at umassmed.edu
